ENDONOVO THERAPEUTICS, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements
ENDONOVO THERAPEUTICS, INC. (ENDV) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements of $109.78 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-04-17.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements · last filed 2023-04-17
- ENDONOVO THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2022 was $109.78K, a 17.70% decline from fiscal 2021.
- ENDONOVO THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2021 was $133.39K, a 92.82% decline from fiscal 2020.
- ENDONOVO THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2020 was $1.86M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 12 month |
|---|---|
| 2022-12-31 | $109.78K 10-K · filed 2023-04-17 |
| 2021-12-31 | $133.39K 10-K · filed 2023-04-17 |
| 2020-12-31 | $1.86M 10-K · filed 2022-04-14 |